Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission

Baloxavir marboxil (BXM) is approved for treating uncomplicated influenza. The active metabolite baloxavir acid (BXA) inhibits cap-dependent endonuclease activity of the influenza virus polymerase acidic protein (PA), which is necessary for viral transcription. Treatment-emergent E23G or E23K (E23G/...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Jeremy C., Zagribelnyy, Bogdan, Pascua, Philippe Noriel Q., Bezrukov, Dmitry S., Barman, Subrata, Okda, Faten, Webby, Richard J., Ivanenkov, Yan A., Govorkova, Elena A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312377/
https://www.ncbi.nlm.nih.gov/pubmed/35830486
http://dx.doi.org/10.1371/journal.ppat.1010698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312377/
https://www.ncbi.nlm.nih.gov/pubmed/35830486
http://dx.doi.org/10.1371/journal.ppat.1010698

Ejemplares similares